Trials / Completed
CompletedNCT05195112
Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the Efficacy and Safety of MT921 in Subjects with Moderate to Severe Submental fat compared with Placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT921 | Active ingredient |
| DRUG | Placebo | Normal Saline |
Timeline
- Start date
- 2021-12-24
- Primary completion
- 2023-02-18
- Completion
- 2023-02-18
- First posted
- 2022-01-18
- Last updated
- 2023-02-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05195112. Inclusion in this directory is not an endorsement.